NAD+ declines with age and is central to energy metabolism and repair, but whether raising it with precursors produces meaningful healthspanTermHealthspanThe period of life spent with preserved function, resilience, and low disease burden.In glossary → benefit in humans remains unsettled.

Sources: [1][2]

Evidence standingEarly human
Key facts
Portal
Longevity Science
Stage
Early human, mixed results
Evidence
Early human
Reversible
Reversible
Reviewed
May 2026
Read time
6 min
Contents

Page status

Needs adequately powered functional-outcome trials · Tissue-level effects unclear

Key takeaways

  • NAD+ is a coenzyme essential to metabolism and to repair enzymes such as sirtuins and PARPs.
  • Precursors like NR and NMN reliably raise blood NAD+ markers, but clinical outcomes are inconsistent.
  • Tissue-level effects and long-term safety are the unresolved questions, not whether levels can be raised.

Mechanism

NAD+ carries electrons in metabolism and is consumed by enzymes that repair DNA and regulate stress responses. Levels fall with age in many tissues, which motivated the idea that restoring NAD+ could restore function.

Supplemental precursors — nicotinamide riboside and nicotinamide mononucleotide — are converted to NAD+ and consistently raise measurable NAD+ metabolites in blood.

What the trials show

Human trials generally confirm that precursors raise NAD+ markers and are well tolerated over the periods studied. Functional benefits — on strength, metabolism, or cardiovascular measures — have been small or inconsistent across studies.

A raised blood marker does not guarantee the relevant tissues benefit, and some biology suggests context matters, including concerns about fueling existing disease. The honest current status is a plausible target with unproven clinical payoff.

Open questions

  • Do raised blood NAD+ levels translate to the tissues that matter?
  • Are there populations where boosting NAD+ is harmful rather than neutral?

Watchlist

Signals that would move this entry along the evidence scale.

Tissue-specific NAD+ measurementAdequately powered outcome trialsLong-term safety

References

  1. Chronic nicotinamide riboside supplementation trial. Martens et al., Nature Communications, 2018
    Showed NR raises NAD+ and is well tolerated, with modest physiological effects.
  2. NAD+ metabolism review. Covarrubias et al., Nature Reviews Molecular Cell Biology, 2021
    Reviews NAD+ decline in aging and the state of precursor evidence.

Cite this page

Future Human Atlas. “NAD+ Metabolism and Boosters.” Last reviewed May 2026. https://future-human-wiki.vercel.app/articles/nad-metabolism

Suggest an edit